Juan MD - Marker Therapeutics COO, CoFounder

Marker Therapeutics Management Efficiency

The company has return on total asset (ROA) of (0.4087) % which means that it has lost $0.4087 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7174) %, meaning that it created substantial loss on money invested by shareholders. Marker Therapeutics' management efficiency ratios could be used to measure how well Marker Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 02/07/2025, Return On Tangible Assets is likely to drop to -0.77. In addition to that, Return On Capital Employed is likely to grow to -1.13. At this time, Marker Therapeutics' Other Current Assets are relatively stable compared to the past year. As of 02/07/2025, Net Tangible Assets is likely to grow to about 53.1 M, while Non Current Assets Total are likely to drop 0.00.

Similar Executives

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. The company was founded in 1999 and is headquartered in Houston, Texas. Marker Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 56 people. Marker Therapeutics (MRKR) is traded on NASDAQ Exchange in USA. It is located in 9350 Kirby Drive, Houston, TX, United States, 77054 and employs 8 people. Marker Therapeutics is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Marker Therapeutics Leadership Team

Marker Stock Performance Indicators

Additional Tools for Marker Stock Analysis